Goserelin Administration Routes and Clinical Context

Administration Routes and Techniques

• The National Comprehensive Cancer Network recommends intramuscular injection as an alternative route, particularly with leuprolide formulations, although the subcutaneous route is standard for goserelin 1
• For breast cancer treatment, the American Society of Clinical Oncology supports subcutaneous goserelin 3.6 mg every 4 weeks or 10.8 mg every 12 weeks, with consideration of appropriate initiation relative to chemotherapy timing 1, 3

Clinical Context Across Indications

• In prostate cancer treatment, subcutaneous administration every 4 weeks with 3.6 mg depot is used, with an alternative 3-month depot available 2
• For ovarian suppression in breast cancer, subcutaneous goserelin 3.6 mg every 4 weeks or 10.8 mg every 12 weeks is recommended, with consideration of chemotherapy timing 3